Home>Topics>Companies>Novo Nordisk

Novo Nordisk

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Novo Nordisk CEO says sees little U.S. pricing pressures

    Headlines

    Fri, 30 Jan 2015

    COPENHAGEN, Jan 30 (Reuters) - Novo Nordisk does not expect pressure on prices for its drugs in the United States, the world's largest pharmaceutical market, Chief Executive Lars Rebien Sorensen told reporters on a conference call on Friday.

  2. UPDATE 1- Novo Nordisk keeps 2015 guidance after strong Q4

    Headlines

    Fri, 30 Jan 2015

    COPENHAGEN, Jan 30 (Reuters) - Denmark's Novo Nordisk maintained its financial guidance for 2015, giving a more detailed number for its sales growth, after a stronger fourth quarter than expected.

  3. RPT- Novo Nordisk keeps 2015 guidance after strong Q4

    Headlines

    Fri, 30 Jan 2015

    COPENHAGEN, Jan 30 (Reuters) - Denmark's Novo Nordisk maintained its financial guidance for 2015, giving a more detailed number for its sales growth, after a stronger fourth quarter than expected.

  4. Novo Nordisk keeps 2015 guidance after strong Q4

    Headlines

    Fri, 30 Jan 2015

    COPENHAGEN, Jan 30 (Reuters) - Denmark's Novo Nordisk maintained its financial guidance for 2015, giving a more detailed number for its sales growth, after a stronger fourth quarter than expected.

  5. Novo Nordisk to launch obesity treatment in EU markets in 2015

    Headlines

    Fri, 23 Jan 2015

    COPENHAGEN, Jan 23 (Reuters) - Novo Nordisk , the world's biggest insulin maker, said on late Thursday it has received a positive opinion from the European regulatory authorities for its obesity treatment Saxenda.

  6. BRIEF- Novo Nordisk says Switzerland first country to launch Xultophy

    Headlines

    Mon, 19 Jan 2015

    Jan 19 (Reuters) - Novo Nordisk A/S : ** Says Switzerland first country to launch Xultophy (IDegLira) for people with type 2 diabetes ** Says expects to make Xultophy available in other countries throughout Europe in 2015 Source text for Eikon:

  7. Novo Nordisk to promote drug to treat obesity in United States

    Headlines

    Mon, 29 Dec 2014

    COPENHAGEN, Dec 29 (Reuters) - Danish pharmaceutical group Novo Nordisk plans to use 500 of its 3,000-strong sales force in the United States to promote its new obesity drug, executive vice president Jakob Riis told Reuters on Monday.

  8. Novo Nordisk CEO sees short-term challenges to growth - paper

    Headlines

    Sat, 27 Dec 2014

    COPENHAGEN, Dec 27 (Reuters) - Novo Nordisk , the world's biggest insulin maker, is confident about its long-term growth plans but needs to secure approval for its new

  9. FDA approves Novo Nordisk's injection for obesity

    Headlines

    Tue, 23 Dec 2014

    Dec 23 (Reuters) - The U.S. health regulator approved a formulation of Novo Nordisk 's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects one in three Americans.

  10. Novo Nordisk gets positive opinion on Tresiba for children in Europe

    Headlines

    Fri, 19 Dec 2014

    COPENHAGEN, Dec 19 (Reuters) - Drug maker Novo Nordisk said the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of its diabetes drug Tresiba for the treatment of children and adolescents.

« Prev12345Next »
Content Partners